COMP <GO>
VMD vs JNJ // EV/EBITDA & P/E VALUATION
Viemed Healthcare Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: VMD 6
— JNJ 6
▲ EV/EBITDA & P/E VALUATION LEADER: VMD
LAST: $9.95 (-0.40%) • MKT CAP: $379.0M
valuation
6.6x
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VMD VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VMD | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.50% | 67.90% | -10.40 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.00% | 25.50% | -12.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 6.6x | 18.5x | -11.90 | VMD | /valuation <GO> |
| Free Cash Flow Yield | 3.15% | 2.97% | +0.18 | VMD | /fcf-yield <GO> |
| Operating Margin | 8.50% | 34.70% | -26.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 5.70% | 28.50% | -22.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 20.50% | 6.00% | +14.50 | VMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.59 | 5.59 | +1.00 | VMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | VMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 62.1 | -8.99 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.7x | 23.0x | -2.30 | VMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $379.0M | $662.49B | -$662.11B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VMD REV | JNJ REV | VMD GROSS % | JNJ GROSS % | VMD FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $270.3M | $94.19B | 57.5% | 67.9% | $11.9M | $19.70B |
| FY 2024 | $224.3M | $88.82B | 59.4% | 69.1% | $1.3M | $19.84B |
| FY 2023 | $183.0M | $85.16B | — | — | $45.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VMD // BETA —
JNJ // BETA 1.08